Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program
Go back to Alterity Therapeutics Announces Expanded ATH434 Phase 2 Clinical Development Program| (NYSE: ATH) | Delayed: 83.33 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $83.33 | 52 Week High | $ | |||
| Open | $83.33 | 52 Week Low | $ | |||
| Day High | $83.33 | P/E | N/A | |||
| Day Low | $83.33 | EPS | $ | |||
| Volume | 7,858 | |||||
| (NASDAQ: ATHE) | Delayed: 3.43 -0.09 (2.56%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.52 | 52 Week High | $ | |||
| Open | $3.57 | 52 Week Low | $ | |||
| Day High | $3.65 | P/E | N/A | |||
| Day Low | $3.41 | EPS | $ | |||
| Volume | 17,332 | |||||
